1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Latin America Liver Cancer Market - Segmented by type, technology, end-user, and geography (2017 - 2022)

Mordor Intelligence analysts forecasted the Latin America Liver Cancer Market to grow at a CAGR of 5-11% over the period, (2017 - 2022). The market is currently valued at USD 35 million for the year 2015.



Liver cancer represents the fifth most commonly occurring cancer and the third leading reason for cancer related deaths in the world. Nearly 800,000 people are annually diagnosed with primary carcinoma. Therefore, the liver cancer medication market is anticipated to become an active ground for competition in the future. Nexavar (sorafenib) is the dominant therapeutic in the market, and is additionally the most important targeted medical aid that is regularly used for advanced-stage carcinoma patients.



With only a few approved drugs within the market and another few in the pipeline, it is a proven fact that incidence and mortality from the sickness continues to rise worldwide. Many new-targeted therapies are expected to enter the market in the following few years. Targeted cancer therapies use medication to prevent the expansion of cancer cells by interrupting certain molecules, known as molecular targets, thereby preventing the progression and growth of cancer cells. The treatment, also known as 'molecular targeted therapy', focuses on the cellular and molecular changes, pertaining specifically to cancer. It is thereby more effective, as compared to the other treatments for cancer, including radiotherapy and chemotherapy.



The Latin America liver cancer market is segmented based on:





Type







Primary

Secondary

Benign liver growths







 Diagnosis







Ultrasound scans

Confirmatory needle biopsy

Endoscopic ultrasound

Laparoscopy

CT scan

PET scan

Magnetic resonance imaging (MRI) scans







Therapeutics







Hepatocellular carcinoma

Cholangiocarcinoma

Hepatoblastoma

Targeted therapy        

Others







End-User







 Pediatrics

Adults







Geography







Argentina

 Brazil.





Some of the key participants in the industry include Bayer Schering Pharma AG, Onyx Pharmaceuticals, Inc., Celsion Corp., Alnylam Pharmaceuticals, Inc., ArQule, Inc., 4SC AG, ImClone Systems Inc., Jennerex Biotherapeutics, Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd., and Bristol-Myers Squibb Company. Etc.



Drivers:





Increasing incidences of cancer

Drug innovations with regard to the cancer

Government initiatives

Rise in aging populace

Excessive alcohol consumptions

High unmet needs for the treatment of liver cancer in the market

Increasing health care expenditure





Restraints:





Low success rate in clinical trials for cancer drugs

Huge capital investments

Low accessibility in remote areas

Stringent regulatory procedures





SPECIALITIES  OF THIS REPORT





The report will be useful in gaining an exhaustive understanding of the regional market. It will also be of assistance in providing a comprehensive analysis of the major trends, innovations and associated prospects for market growth over the coming half a decade.

The report will be an ideal source material for industry consultants,  manufacturers and other interested and allied parties to gain a critical insight into the factors driving and restraining the market, in addition to opportunities offered.

The report contains wide range of information about the leading market players and the major strategies adopted by them.





WHAT THE REPORT OFFERS





Market definition along with identification of key drivers and restraints for the market.

Market analysis with region specific assessments and competition analysis on a global and regional scale.

Identification of factors instrumental in changing the market scenarios, rising prospective opportunities and identification of key companies which can influence the market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market shares.

Identification and analysis of the macro and micro factors that affect the industry on both global and regional scale.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.



Table Of Contents

Latin America Liver Cancer Market - Segmented by type, technology, end-user, and geography (2017 - 2022)
1. Executive Summary                                                                                                    



2. Research Methodology                                                                                                                      



3. Introduction                                                                                                  



                              3.1 Report Description                                                                    



                              3.2 Markets Covered                                                                          



4. Market Overview                                                                                                              



                              4.1 Market Definition                                                                        



                              4.2 Market Drivers                                                                                    



                                                              4.2.1 aging population                                      



                                                              4.2.2 Rising Government and Non-Government Funding for Vaccine Development                                                  



                                                              4.2.3 high unmet needs for the treatment of liver cancer                                                          



                                                              4.2.4 excessive alcohol consumptions                                      



                              4.3 Market Restraints                                                                        



                                                              4.3.1 Techinical Advancements                                  



                                                              4.3.2 Huge Capital Investments                                                                



                                                              4.3.3 Stringent Regulatory Procedures                                    



                                                              4.3.4 Low success rate in clinical trails for cancer drugs                                      



                               4.4 Market Opportunitites                                                                                  



                               4.5 Market Threats                                                                                



5. Porters Five Force Analysis                                                                                                        



                              5.1 Bargaining Power of suppliers                                                                                        



                              5.2 Bargaining power of buyers                                                                



                              5.3 Degree of competition                                                                                    



                              5.4 Threat of substitution                                                                                        



                              5.5 Threat of new entrants                                                                                  



6. Market Segmentation                                                                                                                            



                              6.1 By Type                                                                                



                                                              6.1.1 primary liver cancer                                                          



                                                                                              6.1.1.1 Hepatocellular carcinoma (HCC)  



                                                                                              6.1.1.2 Angiosarcoma        



                                                                                              6.1.1.3 Cholangiocarcinoma (bile duct cancer)        



                                                                                            6.1.1.4 Hepatoblastoma                              



                                                              6.1.2 secondary liver cancer                                              



                                                              6.1.3 Benign liver growths                                                      



                              6.2 Diagnosis                                                                          



                                                              6.2.1 ultrasound scans                                    



                                                              6.2.2 Confirmatory Needle biopsy                                                      



                                                              6.2.3 Endoscopic Ultrasound                                            



                                                              6.2.4 Laparoscopy                                                      



                                                              6.2.5 CT Scan                                          



                                                              6.2.6 PET Scan                                      



                                                              6.2.7 magnetic resonance imaging (MRI) scans                                    



                              6.3 Therapeutics                                                                                            



                                                              6.3.1 Hepatocellular carcinoma                                  



                                                              6.3.2 Cholangiocarcinoma                                                        



                                                              6.3.3 Hepatoblastoma                                      



                                                              6.3.4 Targeted therapy                                  



                                                              6.3.5 Others                                            



                              6.4 By End User                                                                



                                                              6.4.1 Pediatrics                                  



                                                              6.4.2 Adults                                              



                              6.5 By Geography                                                                                      



                                                              6.5.1 Argentina                                



                                                              6.5.2 Brazil                                                    



7. Competitive Landscape                                                                                                                      



                              7.1 Mergers and Acquisitions                                                                                  



                              7.2 Agreements, Collaborations and Partnerships                                                                



                              7.3 New Product Launches                                                                                  



                              7.4 Recommendations to new market players                                                                      



                              7.5 Value Chain Analysis                                                                                            



8. Company Profiles                                                                                                              



                              8.1 Bayer Schering Pharma AG,                                                                



                              8.2 Onyx Pharmaceuticals, Inc., Celsion Corp.,                                                                    



                              8.3 Alnylam Pharmaceuticals, Inc.,                                                                                      



                              8.4 ArQule, Inc.,                                                                                              



                              8.5 4SC AG,                                                                              



                              8.6 ImClone Systems Inc.,                                                                                    



                              8.7 Jennerex Biotherapeutics, Inc.,                                                                                



                              8.8 Pfizer Inc.,                                                                    



                              8.9 F Hoffmann-La Roche Ltd..,                                                                



                              8.10 Bristol-Myers Squibb Company.                                                                            



   9. Appendix                                                                                                          



                              9.1 Abbrevations                                                                                          



                              9.2 Sources                                                                                



                              9.3 Bibliography                                                                                              



                              9.4 Disclaimer                                      

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 52400
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic ...

2017 Global Cancer Diagnostics Market: New Frontiers, Business Challenges, Emerging Technologies, Competitive Landscape

2017 Global Cancer Diagnostics Market: New Frontiers, Business Challenges, Emerging Technologies, Competitive Landscape

  • $ 21100
  • Industry report
  • March 2017
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100. VPGMarketResearch.com's new report is a study of the major business opportunities emerging in the global cance ...

2017 World Cancer Diagnostics Market Future Horizons and Growth Strategies: Supplier Shares by Tumor Marker, Country Segment Forecasts, Competitive Intelligence, Opportunities

2017 World Cancer Diagnostics Market Future Horizons and Growth Strategies: Supplier Shares by Tumor Marker, Country Segment Forecasts, Competitive Intelligence, Opportunities

  • $ 21100
  • Industry report
  • March 2017
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100. VPGMarketResearch.com's new report is a seven-country strategic analysis of the major business opportunities ...


Download Unlimited Documents from Trusted Public Sources

Hepatitis Statistics and Therapy Market in the UK

  • March 2017
    10 pages
  • Hepatitis  

    Therapy  

    Antiviral  

  • United Kingdom  

View report >

Opioid Market in the US

  • March 2017
    13 pages
  • Opioid  

  • United States  

View report >

Opioid Market in the US

  • March 2017
    11 pages
  • Opioid  

  • United States  

    Mexico  

View report >

Related Market Segments :

Cancer

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.